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Abstract 
 Oxadiazoles are a class of heterocyclic aromatic chemical compound of azole family. 
Oxadiazole is five membered heterocycle having two carbons, two nitrogen, one oxygen and 
two double bonds. Oxadiazole exists in four isomeric forms depending upon the position of 
nitrogen atom in the ring. Benzimidazole is a heterocyclic aromatic compound. This bicyclic 
compound consists of fusion of benzene and imidazole. Benzimidazole may also be 
considered as cyclic analogues of imidines due to tautomerism effect. In the present study 
involves synthesis of1,3,4-oxadiazolyl benzenesulphonylbenzimidazole derivatives. All the 
synthesized compounds were screened against HepG-2 cell line to determine the growth 
inhibitory effect of compounds.All the synthesized compounds possessed good to moderate 
anti-cancer activity as compare to standard drug Adriamycin. Two of the synthesized 
compounds i.e. 8a and 8f were found to possess maximum anti-cancer activity.The structures 
of the synthesized compounds were established by IR and 1HNMR. 
Introduction 
Cancer is a term given to diseases in which the cells divide 
abnormally and can invade other parts of body. One defining 
feature of cancer is the rapid creation of abnormal cells that 
grow beyond their usual boundaries, and which can then 
invade adjoining parts of the body and spread to other organs, 
the latter process is referred to as metastasizing.Cancer is 
considered to be the second most common cause of deaths 
after cardiovascular diseases in the world. Despite 
significantprogress has been achieved in anti-cancer therapy, 
the discoveryand development of effective anticancer drugs 
remain one ofthe most intractable worldwide health 
problems[1]. According to information from the World Health 
Organisation (WHO), it is estimated that there will be 12 
million deaths from cancer in 2030. Numbers of clinically 
used compounds such as vincaalkaloids, colchicines, 
paclitaxel, and epothilone as anti-cancer agents attack 
microtubules by interfering with thedynamics of the tubulin 
polymerization and depolymerization, resulting in mitotic 
arrest[2-5].Undoubtedly, targeting tubulin is a successful 
strategy for cancer chemotherapy, however, thereare still 
many problems existing in clinical use of these anti-tubulin 
agents, like toxicity, poorwater solubility, poor bioavailability 
and multi-drug-resistant (MDR)[6-8]. Oxadiazoles are a class 
of heterocyclic aromatic chemical compound of azole family. 
Oxadiazole is five membered heterocycle having two carbons, 
two nitrogen, one oxygen and two double bonds [9]. 
Oxadiazole moiety and its various derivatives studied 
frequently in the past few decades and found potent in various 
pharmacological and pathological conditions. Due to its wide 
range of activities vizanti-cancer [10], anti-bacterial [11], anti-
fungal [12], anti-tubercular [13], anti-convulscant[14], anti-
inflammatory [15] a steady research is going on in oxadiazole 
nucleus.1,2,5-oxadiazole, 1,2,4-oxadiazole, 1,3,4-oxadiazole 
are known but 1,2,3-oxadiazole is unstable ring open to form 
diazoketone tautomer. 1,3,4-oxadiazoles is a thermally stable 
molecule. The 1,3,4-oxadiazole undergoes number of 
reactions including electrophillic substitution, nucleophilic 
substitution, thermal and photochemical[16].1,3,4-oxadiazole 
have  been extensively studied for the identification of 
potential anticancer agents. Recent studies have indicated that 
1,3,4-oxadiazole derivatives exhibit potent anti-cancer activity 
against different cancer cell lines through the inhibition of 
different growth factors, enzymes and kinases including 
telomerase, histone deacetylase (HDAC), methionine 
aminopeptidase (MetAP), thymidylate synthase (TS), 
glycogen synthase kinase-3 (GSK), epidermal growth factor 
(EGF), vascular endothelial growth factor (VEGF), and focal 
adhesion kinase (FAK)[17]. The SAR studies revealed that the 
antitumor activity is dependent on the nature of the 
substituents at position 2 of 1,3,4-oxadiazoles [18].Most active 
1,3,4-oxadiazoles have been seen to inhibit tubulin 
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polymerization or destabalise the microtubule system. For 
example Zibotentanis a marketed compound based upon 
1,3,4-oxadiazole and possess excellent anti-cancer activity. It 
is an endothelial receptor antagonist and used for treatment of 
prostate cancer [19].Benzimidazole is a heterocyclic aromatic 
compound. This bicyclic compound consists of fusion of 
benzene and imidazole. Benzimidazole may also be 
considered as cyclic analogues of imidines due to tautomerism 
effect. Benzimidazole acts as phamacophore ring to synthesize 
biologically active moieties [20].Benzimidazole and its 
derivatives exhibit various pharmacological activities such as 
anti-cancer [21], anti-HIV [22], anti-inflammatory [23], anti-
microbial [24], making it an indispensable anchor for the 
development of various new therapeutic agents. The most 
commonly used approach to synthesize benzimidazole 
includes condensation of arylenediamine with a carbonyl 
equivalent. For example Bendamustine is a marketed and 
potent anti-cancer agent based on benzimidazole nucleus. It 
functions as an alkylating agent and causes both inter and 
intra-strand cross-links between DNA bases resulting in cell 
death [25]. 
Experimental 
The commercial chemicals employed for the present work 
were purchased from Spectrochem, Sigma-Aldrich, Merck 
India and Loba Chem. All the solvents were used after 
distillation. Thin layer chromatography was performed on E 
Merck silica gel 60F254precoated plates and the identification 
was done under UV light. Various solvent systems used for 
developing chromatograms were ethyl acetate: n-hexane: 
methanol, n-hexane: ethyl acetate, benzene: acetone and ethyl 
acetate: hexane. Melting points were determined using melting 
point apparatus (Perfit India) by capillary method and are 
uncorrected. The identification and characterization of the 
compounds were carried out by determining melting point, IR 
and 1HNMR. All the infra red (IR) spectra were recorded on 
Bruker α-E FTIR-ATR. 1H NMR was recorded on Bruker 
Avance 2400 (400MHz) spectrometer using DMSO and 
CDCl3as solvent at SAIF, Punjab University, Chandigarh and 
JEOL JNM-ECS400 (400MHz) spectrometer at Indian 
Institute of Technology (IIT). 
Synthesis of benzimidazole (2a) 
The mixture of o-phenylenediamine (5.43g, 0.04mol) and 
formic acid (3ml, 0.06mol) was heated on a water bath for 2 
hours at 100°C. Cooled and then added 10% of sodium 
hydroxide solution until the mixture is just alkaline to litmus. 
Then above solution was filtered and washed with cold water 
twice. Then dissolved in boiling water and then added 
charcoal (1g) and then filtered hot, pure crystals were 
obtained. 
Benzimidazole (2a): State: Colourless crystals; Yield: 75%; 
Melting point: 170-172°C; Rf 0.25 (Ethyl acetate: n-hexane: 
methanol, 3:2:1);IR (ν, cm-1):1652 (C=N), 3107 (Ar-C-H), 
1588 (Ar-C=C), 3107 (N-H); 1HNMR (CDCl3) 7.1-7.9 (m, 
4H, Ar-H), 11.7 (s, 1H, NH). 
Synthesis of 2-methyl benzimidazole (2b) 
Heat the mixture of o-phenylenediamine dihydrochloride 
(5.42g, 0.03mol) and acetic acid (5.4ml, 0.09mol) and water 
(20 ml) under reflux for 45 minutes. Then the reaction was 
cooled and then basify by gradual addition of concentrated 
ammonia solution. Precipitates formed were recrystallized 
from 10% ethanol. 
2-methyl benzimidazole (2b): State: Beige crystalline 
powder; Yield: 78%; Melting point: 176°C; Rf 0.46 (Ethyl 
acetate: n-hexane: methanol, 3:2:1);IR (ν, cm-1):1618(C=N), 
3047 (Ar-C-H), 1547 (Ar-C=C), 2978 (N-H); 1HNMR(CDCl3) 
2.51 (s, 3H, CH3), 7.11-7.14 (m, 2H, Ar-H), 7.46-7.49 (m, 2H, 
Ar-H). 
Synthesis of ester derivatives (4a-4e) 
4-substituted benzoic acid (3a-3e) (8g)was dissolved in 
ethanol or methanol (20ml, 0.4mol) and then concentrated 
sulphuric acid (3ml, 0.03mol) was added which acts as 
catalyst. Then the above mixture was refluxed for 3-4 hours. 
Then the solution was cooled to room temperature. 
Precipitated formed were filtered out and recrystallized from 
ethanol to obtain ester derivatives (4a-4e). 
4-Nitrobenzoic acid ethyl ester (4a): State: Colourless 
crystals; Yield: 82%; Melting point: 54-55°C; Rf 0.32 (Ethyl 
acetate: hexane 3:1);IR (ν, cm-1):3114(Ar-C-H), 1710 (C=O), 
1093 (C-O), 1600 (Ar-C=C), 1343 (Ar-NO2); 1HNMR 
(DMSO-d6) 8.26-8.45 (m, 2H, Ar-H), 8.26-8.12 (m, 2H, Ar-
H), 4.44 (q, J=7.2 Hz, 2H, CH2), 1.44 (t, J=7.1 Hz, 3H, CH3). 
4-Chlorobenzoic acid methyl ester (4b):State: White 
crystals; Yield: 80%; Melting point: 40-42°C; Rf 0.39 (Ethyl 
acetate: hexane 3:1);IR (ν, cm-1):3135 (Ar-C-H), 1726 (C=O), 
1113 (C-O), 1597 (Ar-C=C), 760 (Ar-Cl); 1HNMR (DMSO-
d6) 7.94 (d, J=8.6 Hz, 2H, Ar-H), 7.37 (d, J=8.6 Hz, 2H, Ar-
H), 3.87 (s, 3H, CH3). 
4-Fluorobenzoic acid ethyl ester (4c):State: Yellow powder; 
Yield: 78%; Melting point: 25-27°C; Rf 0.65 (Ethyl acetate: 
hexane 3:1);IR (ν, cm-1):3104(Ar-C-H), 1723 (C=O), 1083 (C-
O), 1580 ( Ar-C=C), 1350 (Ar-F); 1HNMR (DMSO-d6) 8.04-
8.09 (m, 2H, Ar-H), 7.08-7.14 (m, 2H, Ar-H), 4.38 (q, J=7.0, 
2H, CH2), 1.40 (t, J=7.0 Hz, 3H, CH3). 
4-Bromobenzoic acid methyl ester (4d):State: White 
powder; Yield: 76%; Melting point: 77-80°C; Rf 0.32 (Ethyl 
acetate: hexane 3:1);IR (ν, cm-1):3130 (Ar-C-H), 1721 (C=O), 
1110 (C-O), 1592 (Ar-C=C), 660 (Ar-Br); 1HNMR (DMSO-
d6) 7.87 (d, J=8.6 Hz, 2H, Ar-H), 7.55 (d, J=8.6 Hz, 2H, Ar-
H), 3.87 (s, 3H, CH3). 
4-hydroxybenzoic acid ethyl ester (4e):State: White 
crystalline powder; Yield: 85%; Melting point: 115-116°C; Rf 
0.24 (Ethyl acetate: hexane 3:1);IR (ν, cm-1):3105 ( Ar-C-H), 
1730 (C=O), 1082 (C-O), 1578 ( Ar-C=C), 3200 (Ar-OH); 
1HNMR (DMSO-d6) 7.87 (d, J=8.9 Hz, 2H, Ar-H), 6.81 (d, 
J=8.9 Hz, 2H, Ar-H), 4.3 (q, J=7.1 Hz, 2H, CH2), 1.36 (t, 
J=7.1 Hz, 3H, CH3), 5.0 (s, 1H,OH). 
Synthesis of Hydrazide derivatives (5a-5e) 
Mixture of compound (4a-4b) (9.5g) and ethanol (30ml, 
0.6mol) was added to hydrazine hydrate (11ml, 0.2mol) and 
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the reaction mixture was refluxed for 3 hours. After cooling 
the solid precipitated was filtered, washed with ethanol, dried 
and recrystallized from ethanol to obtain desired derivatives 
(5a-5e).  
4-Nitrobenzoic acid hydrazide (5a): State: Yellow powder; 
Yield: 75%; Melting point: 210-213°C; Rf 0.54 (n-hexane: 
ethyl acetate 3:1);IR (ν, cm-1):1640 (C=O), 2850 (Ar- C-H), 
1540 (Ar-C=C), 3300 (N-H), 1596 (N-H), 1340 (Ar-NO2); 
1HNMR (DMSO-d6) 7.29-7.86 (m, 4H, Ar-H), 2.0 (s, 1H, 
NH), 4.13-4.14 (d, J=4, 2H, NH2). 
4-Chlorobenzoic acid hydrazide (5b):State: White crystals; 
Yield: 72%; Melting point: 260-262°C; Rf 0.56 (n-hexane: 
ethyl acetate 3:1);IR (ν, cm-1):1655 (C=O), 2853(Ar-C-H), 
1472 (Ar-C=C), 3304 (N-H), 1598 (N-H), 716 (C-Cl); 
1HNMR (DMSO-d6) 7.45-7.89 (m, 4H, Ar-H), 2.0 (s, 1H, 
NH), 8.0 (s, 2H, NH2). 
4-Fluorobenzoic acid hydrazide (5c):State: White powder; 
Yield: 76%; Melting point: 162-164°C; Rf 0.52 (n-hexane: 
ethyl acetate 3:1);IR (ν, cm-1):1593 (C=O), 2864 (Ar-C-H), 
1522 (Ar-C=C), 3049 (N-H), 1543 (N-H), 1342 (Ar-F). 
4-Bromobenzoic acid hydrazide (5d):State: Light beige 
powder; Yield: 78%; Melting point: 167-169°C; Rf 0.62 (n-
hexane: ethyl acetate 3:1);IR (ν, cm-1):1533 (C=O), 2866 (Ar-
C-H), 1519 ( Ar-C=C), 3051(N-H), 1549 (N-H), 662 (Ar-F). 
4-Hydroxybenzoic acid hydrazide (5e):State: Beige crystals; 
Yield: 74%; Melting point: 264-266°C; Rf 0.51 (n-hexane: 
ethyl acetate 3:1);IR (ν, cm-1):1538 (C=O), 2861 (Ar- C-H), 
1523 (Ar-C=C), 3054 (N-H), 1546 (N-H), 3190 (Ar-OH). 
Synthesis of 2-(4-substituted)-5-phenyl-[1,3,4]oxadiazole 
derivatives (6a-6e) 
Benzoic acid (3.5g, 0.02mol) was mixed with hydrazide 
derivative (5g) (5a-5e) and then 25 ml of phosphorus 
oxychloride (22ml, 0.1mol) was added on crushed ice. Then 
the above mixture was refluxed on heating mantle at low 
temperature for 2-3 hours. Then after completion of the 
reaction, the above solution was cooled to room temperature 
and then poured on ice. The precipitates formed were filtered, 
dried and recrystallised from ethanol.  
2-(4-nitro-phenyl)-5-phenyl-[1,3,4]oxadiazole (6a):State: 
Off-white solid; Yield: 88%; Melting point: 144-146°C; Rf 
0.62 (Benzene: acetone 7:3);IR (ν, cm-1):3145 (Ar-C-H), 1478 
(Ar-C=C), 1016 (C-O-C), 1590 (C=N), 1542 (Ar-NO2); 
1HNMR (CDCl3) 7.61-7.64 (t, J=6 Hz, 4H, Ar-H), 8.12-8.15 
(t, J= 12Hz, 5H, Ar-H). 
2-(4-chloro-phenyl)-5-phenyl-[1,3,4]oxadiazole (6b):State: 
Off-white powder; Yield: 82%; Melting point: 150-152°C; Rf 
0.54 (Benzene: acetone 7:3);IR (ν, cm-1):3134 (Ar-C-H), 1489 
(Ar-C=C), 1009 (C-O-C), 1598 (C=N), 783 (Ar-Cl); 1HNMR 
(CDCl3) 7.49-7.53 (m, 5H, Ar-H), 8.06 (d, J= 8.0 Hz, 2H, Ar-
H), 8.11 (d, J=6.6 Hz, 2H, Ar-H). 
2-(4-fluoro-phenyl)-5-phenyl-[1,3,4]oxadiazole (6c):State: 
Off-white solid; Yield: 85%; Melting point: 138-140°C; Rf 
0.76 (Benzene: acetone 7:3);IR (ν, cm-1):3052 (Ar-C-H), 1472 
(Ar-C=C), 1003 (C-O-C), 1545 (C=N), 1399 (Ar-Cl); 1HNMR 
(CDCl3) 7.22-727 (m, 2H, Ar-H), 7.54-7.57 (m, 3H, Ar-H), 
8.13-8.18 (m, 4H, Ar-H). 
2-(4-bromo-phenyl)-5-phenyl-[1,3,4]oxadiazole (6d):State: 
Light-brown solid; Yield: 87%; Melting point: 155-157°C; Rf 
0.65 (Benzene: acetone 7:3);IR (ν, cm-1):3267 (Ar-C-H), 1467 
(Ar-C=C), 1018 (C-O-C), 1560 (C=N), 664 (Ar-Br). 
4-(5-phenyl-[1,3,4]oxadiazole-2-yl)-phenol (6e):State: Off-
white solid; Yield: 81%; Melting point: 170-172°C; Rf 0.69 
(Benzene: acetone 7:3);IR (ν, cm-1):3167 (Ar-C-H), 1457 (Ar-
C=C), 1012 (C-O-C), 1550 (C=N), 3190 (Ar-OH); 1HNMR 
(CDCl3) 7.55-7.69 (m, 4H, Ar-H), 8.10-8.18 (m, 5H, Ar-H), 
11.08 (s, 1H, OH). 
Synthesis of 1,3,4-oxadiazolyl benzene sulfonyl 
benzimidazole derivative (8a-8j) 
Substituted 1,3,4-oxadiazole derivative (6a-6e) (0.01mol) was 
mixed with chlorosulphonic acid (0.01mol) in equimolar 
proportions. This mixture was stirred for 30 minutes using 
mechanical stirrer. After stirring, the mixture was heated on 
boiling water bath for 2 hours. After completion of reaction, 
the solution was cooled to room temperature and then poured 
on ice. Precipitates formed were filtered and dried to obtain 
the desired derivatives (7a-7e).Firstly 4-(5-phenyl-
[1,3,4]oxadiazole-2-yl)-benzenesulphonyl derivative (7a-7e) 
(0.05mol)was mixed with benzimidazole (2a) (0.59g, 
0.005mol) and then dichloromethane (30ml, 0.3mol) and 
pyridine (1ml, 0.01mol) was added to above mixture. The 
above solution was stirred for 2-3 hours using mechanical 
stirrer. After completion of reaction, excess of solvent was 
removed by heating. After cooling, the precipitates formed 
were filtered out. Excess of pyridine was removed by using 
petroleum ether. The same procedure was repeated for 
reaction of 2-methylbenzimidazole (2b) and 4-(5-phenyl-
[1,3,4]oxadiazole-2-yl)-bensulphonyl derivative (7a-7e). Final 
precipitates were recrystallised using ethanol to obtain the 
final derivatives.  
 
2.7.1 1-{4-[5-(4-nitro-phenyl)-[1,3,4]oxadiazole-2-yl]-
benzenesulphonyl}-1H-benzimidazole (8a):State: Off-white 
powder; Yield: 77%; Melting point: 251-252°C; Rf 0.56 (Ethyl 
acetate: hexane 3:1);IR (ν, cm-1):1507 (Ar-C=C), 3096 (Ar-C-
H), 1058 (S=O), 1602 (C=N), 1157 (C-O-C), 1330 (Ar-NO2); 
1HNMR (DMSO) 8.35-8.41 (m, 4H, Ar-H), 8.1 (s, 2H, Ar-H), 
7.63-7.65 (t, J=4 Hz, 4H, Ar-H), 7.2-73 (d, J=9 Hz, 2H, Ar-
H), 8.6 (s, 1H, CH). 
1-{4-[5-(4-chloro-phenyl)-[1,3,4]oxadiazole-2-yl]-
benzenesulphonyl}-1H-benzimidazole (8b): State: Light-
brown powder; Yield: 76%; Melting point: 254-259°C; Rf 0.67 
(Ethyl acetate: hexane 3:1);IR (ν, cm-1):1544 (Ar-C=C), 3057 
(Ar-C-H), 1068 (S=O), 1599 (C=N), 1002 (C-O-C), 736 (Ar-
Cl); 1HNMR (DMSO) 7.60-7.68 (m, 8H, Ar-H), 8.5 (s, 1H, 
CH), 8.10-8.12 (t, J=4.4 Hz, 2H, Ar-H), 7.26 (s, 2H, Ar-H). 
1-{4-[5-(4-fluoro-phenyl)-[1,3,4]oxadiazole-2-yl]-
benzenesulphonyl}-1H-benzimidazole (8c):State: Beige 
powder; Yield: 79%; Melting point: 260-262°C; Rf 0.62 (Ethyl 
acetate: hexane 3:1);IR (ν, cm-1):1544 ( Ar-C=C), 2999 (Ar-C-
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H), 1062 (S=O), 1675 (C=N), 999 (C-O-C), 1233 (Ar-F); 
1HNMR (DMSO) 7.28-7.65 (m, 8H, Ar-H) 8.16 (s, 2H, Ar-H), 
8.08-8.10 (d, J=8 Hz, 2H, Ar-H), 8.68 (s, 1H, CH). 
 
1-{4-[5-(4-bromo-phenyl)-[1,3,4]oxadiazole-2-yl]-
benzenesulphonyl}-1H-benzimidazole (8d):State: Off-white 
powder; Yield: 78%; Melting point: 265-267°C; Rf 0.63 (Ethyl 
acetate: hexane 3:1);IR (ν, cm-1):1590 (Ar-C=C), 2973 (Ar-C-
H), 1063 (S=O), 1590 (C=N), 999 (C-O-C), 607 (Ar-Br); 
1HNMR (DMSO) 7.23-7.62 (m, 12H, Ar-H), 8.56 (s, 1H, CH). 
4-{5-[4-(benzimidazol-1-sulphonyl)-phenyl]-
[1,3,4]oxadiazole-2-yl}-phenol (8e):State: Off-white semi-
solid; Yield: 73%; Melting point: 256-258°C; Rf 0.65 (Ethyl 
acetate: hexane 3:1);IR (ν, cm-1):1550 (Ar-C=C), 3065 (Ar-C-
H), 1070 (S=O), 1606 (C=N), 1011 ( C-O-C), 2763 (Ar-OH); 
1HNMR (DMSO) 7.29-8.27 (m, 12H, Ar-H), 8.6 (bs, 1H, CH), 
9.2 (s, 1H, OH). 
1-{4-[5-(4-nitro-phenyl)-[1,3,4]oxadiazole-2-yl]-
benzenesulphonyl}-2-methyl-1H-benzimidazole (8f):State: 
Beige powder; Yield: 75%; Melting point: 240-242°C; Rf 0.52 
(Ethyl acetate: hexane 3:1);IR (ν, cm-1):1507 (Ar-C=C), 3096 
(Ar-C-H), 1058 (S=O), 1602 (C=N), 1247 (C-O-C), 1330 (Ar-
NO2),1331 (CH3); 1HNMR (DMSO) 7.59-7.65 (m, 5H, Ar-H), 
8.12-8.14 (d, J=6 Hz, 2H, Ar-H), 8.37-8.43 (m, 5H, Ar-H), 
2.45-2.46 (t, J=1.8 Hz, 3H, CH3). 
1-{4-[5-(4-chloro-phenyl)-[1,3,4]oxadiazole-2-yl]-
benzenesulphonyl}-2-methyl-1H-benzimidazole (8g):State: 
Beige coloured powder; Yield: 72%; Melting point: 234-
236°C; Rf 0.59 (Ethyl acetate: hexane 3:1);IR (ν, cm-1): 1583 
(Ar-C=C), 3057 (Ar-C-H), 1076 (S=O), 1628 (C=N), 1220 (C-
O-C), 747 (Ar-Cl), 1405 (CH3); 1HNMR (DMSO) 8.54-8.55 
(d, J=4.4 Hz, 2H, Ar-H), 7.59-7.68 (m, 8H, Ar-H), 8.1 (s, 2H, 
Ar-H), 2.69 (s, 3H, CH3). 
1-{4-[5-(4-fluoro-phenyl)-[1,3,4]oxadiazole-2-yl]-
benzenesulphonyl}-2-methyl-1H-benzimidazole (8h):State: 
Off-white powder; Yield: 69%; Melting point: 221-223°C; Rf 
0.57 (Ethyl acetate: hexane 3:1);IR (ν, cm-1):1544 (Ar-C=C), 
3062 (Ar-C-H), 1068 (S=O), 1603 (C=N), 1225 (C-O-C), 
1298 (Ar-F), 1412 (CH3); 1HNMR (DMSO)7.42-8.16 (m, 
12H, Ar-H), 2.7 (s, 3H, CH3). 
1-{4-[5-(4-bromo-phenyl)-[1,3,4]oxadiazole-2-yl]-
benzenesulphonyl}-2-methyl-1H-benzimidazole (8i):State: 
Reddish powder; Yield: 70%; Melting point: 251-254°C; Rf 
0.61 (Ethyl acetate: hexane 3:1);IR (ν, cm-1):1586 ( Ar-C=C), 
2720 (Ar-C-H), 1063 (S=O), 1674 (C=N), 1216 (C-O-C), 608 
(Ar-Br), 1393 (CH3); 1HNMR (DMSO) 7.28-7.60 (m, 12H, 
Ar-H), 2.62 (s, 3H, CH3). 
4-{5-[4-(2-methyl-benzimidazol-1-sulphonyl)-phenyl]-
[1,3,4]oxadiazole-2-yl}-phenol (8j):State: Brown semi-solid; 
Yield: 71%; Melting point: 234-236°C; Rf 0.69 (Ethyl acetate: 
hexane 3:1);IR (ν, cm-1):1548 (Ar-C=C), 2746 (Ar-C-H), 1070 
(S=O), 1606 (C=N), 1214 (C-O-C), 3060 (Ar-OH), 1412 
(CH3); 1HNMR (DMSO) 7.1-8.2 (m, 12H, Ar-H), 2.8 (s, 3H, 
CH3), 8.6 (s, 1H, OH). 
 
Anticancer Evaluation 
 In-vitro anti-cancer screening 
The anticancer screening of all the synthesized compounds 
was conducted against human lung cancer cells line (HepG-2) 
to determine the growth inhibitory effects of the compounds. 
Source of cell line was NCI, USA. Vehicle used for testing 
was Dimethylsulfoxide (DMSO). In vitro testing was done 
using SRB assay protocol; each derivative was tested at 4 dose 
levels (10 µg/ml, 20 µg/ml, 40 µg/ml, 80 µg/ml).  
Using the seven absorbance measurements [time zero (Tz), 
control growth (C), and test growth in the presence of drug at 
the five concentration levels (Ti)], the percentage growth is 
calculated at each of the drug concentrations levels. 
Percentage growth inhibition is calculated as:  
[(Ti-Tz)/(C-Tz)] x 100 for concentrations for which Ti>/=Tz 
[(Ti-Tz)/Tz] x 100 for concentrations for which Ti<Tz. 
Three dose response parameters GI50, total growth inhibition 
(TGI) and LC50were calculated for every compound. 
 
 Results and Discussion 
As per the proposed protocol the synthesis of 1,3,4-
oxadiazolyl benzenesulphonylbenzimidazole derivatives was 
carried out. The yield (%) of the said derivatives was found to 
be in the range of 50-84. The melting point of compounds 
ranged from 234-267˚C and are uncorrected. The Rfwere 
observed in ranges of 0.52-0.69 using different solvents and 
detecting system(Table 1). IR spectrum of benzimidazole 
showed C=N stretch at 1400-1650 cm-1aromatic C-H stretch at 
3000-3200 cm-1and a broad N-H stretch at 2800-3300 cm-1. 
The benzoic acid ester derivatives indicated characteristic 
C=O stretch at 1700-1725cm-1, aromatic C-H stretch at 2970 
cm-1. IR spectrum of oxadiazole derivatives showed an 
absorption at 1615 cm-1which confirmed the presence of 
(C=Nstr), an absorption at 1218 cm-1was due to presence of 
(C-O-Cstr), an absorption at 3048 cm-1 was due to presence of 
(C-Hstr). IR spectrum of final compound showed an additional 
absorption at 1050 cm-1due to presence of sulphoxide group.  
Solvent used for 1HNMR spectrum was DMSO. The 1HNMR 
spectrum of 1,3,4-oxadiazolyl benzenesulphonyl 
benzimidazole derivatives in general showed multiplet in the 
range of δ 8.1-8.4 for 4 aromatic protons of benzene  ring of 
benzimidazole, another multiplet in the range of δ 7.2-7.6 for 
4 aromatic protons of benzene ring attached to oxadiazole, a 
singlet at δ 8.6 confirmed the presence of N=CH and also a 
singlet in the range of 2.4-2.7 due 3 protons of CH3. 
 Anticancer Drug Screening 
All the synthesized compounds were screened against human 
lung cancer cell line (HepG-2) Sto determine the growth 
inhibitory effect of compounds. In vitro testing was done 
using SRB assay protocol, each derivative was tested at 4 dose 
levels (10 µg/ml, 20 µg/ml, 40 µg/ml, 80 µg/ml).   
The synthesized1,3,4-oxadiazolyl benzenesulfonyl 
benzimidazole derivatives exhibited encouraging anticancer 
results. The order for the % control growth inhibition of 
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HepG-2 was found to be 8g<8i<8h<8j<8e<8b<8d<8c(Table 
2). Compounds (8a & 8f) inhibited 50% of the cell growth at 
the conc. <10 µg/ml. The compound 8f and 8g inhibited the 
total cell growth at the conc. <10 and 65.9 µg/ml 
respectivelyfor Andriamycin(Table 3). The results pertaining 
to GI50 and LC50 have been presented in the Table 3and Figure 
2.From the in-vitro analysis it has been found that compounds 
substituted with electron withdrawing group for e.g. NO2, F, 
Cl, Br had better activity. The activity was directly 
proportional to the conc. of the compounds utilised to carry 
out the activity. The graphical representation showed that if 
the experiments were carried out at increased concentrations 
then the compounds would have shown better anti-cancer 
activity. 
 
Conclusion 
In   conclusion,   a   total of   ten 1,3,4-oxadiazolyl 
benzenesulfonyl benzimidazole derivative (8a-8j), have been 
synthesized and evaluated  for  their  anti-cancer activity.  
Among these synthesized heterocycles,   compound 8a and 
8fwere found to possess maximum anti-cancer activity. From 
the in-vitro analysis it has been found that compounds 
substituted with electron withdrawing group for e.g. NO2, F, 
Cl, Br had better activity. The derivatives of 1,3,4-oxadiazolyl 
benzenesulphonyl benzimidazolecan be explored further for 
better anti-cancer activity by extensively studying the SAR 
(Structure Activity Relationship) as well as carrying out by 
fluorescent tubulin intensity assay method. 
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Table 1: Physical Characteristics of synthesized compounds (8a-j) 
Comp. No. Molecular   formula Colour Melting point (°C) Rf* Yield (%) 
8a C21H13N5O5S Off-white 251-252 0.56 77 
8b C21H13ClN4O3S Light-brown 254-259 0.67 76 
8c C21H13FN4O3S Beige 260-262 0.62 79 
8d C21H13BrN4O3S Off-white 265-267 0.63 78 
8e C21H14N4O4S Off-white 256-258 0.65 73 
8f C22H15N5O5S Beige 240-242 0.52 75 
8g C22H15ClN4O3S Beige 234-236 0.59 72 
8h C22H15FN4O3S Off-white 221-223 0.57 69 
8i C22H15BrN4O3S Reddish 251-254 0.61 70 
8j C22H16N4O4S Brown 234-236 0.69 71 
*Ethyl acetate: hexane (3: 1) 
Table 2: In vitro percentage control growth of Human lung cancer cell line HepG-2 at different molar drug concentrations 
C. 
No. 
Drug Concentrations (µg/ml) 
(Experiment 1) (Experiment 2) (Experiment 3) Average % control growth 
10 20 40 80 10 20 40 80 10 20 40 80 10 20 40 80 
8a 24.2 43.7 43.8 
38.
4 
20.8 22.1 25.7 31.6 28.1 25.1 22.0 27.2 24.4 30.3 30.5 32.4 
8b 
114.
7 
126.
7 
113.
4 
89.
9 
113.
8 
108.
4 
98.5 90.8 
123.
8 
110.
6 
96.3 85.2 
117.
4 
115.
2 
102.
7 
88.6 
8c 
117.
7 
120.
8 
95.5 
49.
8 
113.
8 
102.
0 
86.5 54.7 
113.
9 
109.
5 
88.8 52.3 
115.
1 
110.
8 
90.3 52.3 
8d 
117.
2 
118.
1 
105.
7 
69.
0 
108.
9 
104.
1 
89.8 65.9 
117.
3 
107.
6 
95.0 72.6 
114.
5 
109.
9 
96.8 69.1 
8e 
125.
7 
123.
2 
124.
5 
96.
9 
116.
8 
112.
4 
104.
3 
100.
5 
129.
8 
119.
7 
116.
7 
103.
3 
124.
1 
118.
4 
115.
2 
100.
3 
8f 32.8 32.1 42.2 
30.
1 
17.7 18.3 20.1 27.7 26.2 28.6 27.8 33.0 25.5 26.3 30.1 30.2 
8g 
116.
0 
103.
2 
76.6 
74.
0 
115.
2 
99.5 80.4 74.6 
124.
2 
106.
2 
88.1 81.0 
118.
4 
103.
0 
81.7 76.6 
8h 96.3 85.8 80.1 
78.
7 
111.
7 
89.6 80.2 71.0 
114.
0 
110.
0 
94.4 78.2 
107.
3 
95.1 84.9 76.0 
8i 99.4 92.7 82.3 
62.
4 
109.
5 
95.7 79.4 64.0 
117.
2 
116.
6 
99.7 74.2 
108.
7 
101.
7 
87.1 66.9 
8j 
111.
4 
109.
9 
99.1 
99.
6 
115.
2 
112.
3 
97.4 94.2 
127.
3 
135.
5 
123.
4 
100.
7 
118.
0 
119.
2 
106.
6 
98.2 
AD
R 
-35.2 -53.6 -61.4 
-
47.
3 
-39.1 -58.1 -65.4 -54.5 -29.7 -42.8 -56.1 -46.7 -34.7 -51.5 -61.0 -49.5 
Table 3: TGI, LC50 and GI50 of the synthesized compounds against Human lung cancer cell line HepG-2 
C. No.  LC50 (µg/ml) TGI (µg/ml) GI50(µg/ml) 
8a NE NE <10 
8b NE NE >80 
8c NE NE >80 
8d NE NE >80 
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8a     H          NO2           8f     CH3           NO2
8b     H           Cl           8g    CH3           Cl
8c     H            F           8h     CH3           F
8d     H           Br           8i      CH3          Br
8e     H           OH         8j       CH3         OH
 
Reagents and Conditions: a) heat at 100°C, 2hb) NaHCO3, CCl4, reflux ,4h c) hydrazine hydrate, ethanol, reflux, 3h d)C6H5COOH, 
POCl3, reflux, 4he) chlorosulphonic acid, DCM, 50°C f) pyridine, DCM, rt, 2h. 
Figure 1: Reaction scheme for the synthesis of 1,3,4-oxadiazolylbenzenesulfonylbenzimidazole derivatives 
8e NE NE >80 
8f NE <10 <10 
8g NE 65.9 >80 
8h NE NE >80 
8i NE NE >80 
8j NE NE >80 
ADR 43.56 <10 <10 
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Figure 2: Graph showing % control growth against the drug concentrations (8a-8sj) and standard Andriamycin 
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